|
|
Click to share this burst with your friends and colleagues! 
THE RIGHT TREATMENT | FOR THE RIGHT PATIENT | AT THE RIGHT TIME | EVERY TIME
|
|
FDA Office of Clinical Pharmacology Announces Availability of 2024 Annual Report |
|
|
Today, the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Translational Sciences (OTS), Office of Clinical Pharmacology (OCP) announced the availability of the 2024 OCP Annual Report. OCP is a dynamic, purpose-driven organization dedicated to promoting and protecting global public health through the application of clinical pharmacology and translational medicine principles.
In this year’s report, OCP’s highly committed staff and partners continued to collaborate, apply scientific innovation, and demonstrate excellence across all relevant scientific and therapeutic areas. OCP was also critical in establishing the CDER Quantitative Medicine Center of Excellence (QM CoE), an alliance of several CDER Offices dedicated to maximizing synergies in innovative methods and technologies that will advance drug development and improve public health.
Learn more about OCP’s dedication to excellence, collaborative achievements, and 2025 outlook in the 2024 OCP Annual Report. To access past OCP annual reports and learn more about OCP, visit the OCP webpage.
|
|
|
The Office of Clinical Pharmacology (OCP) is pleased to offer the e-mail subscription service Clinical Pharmacology Corner. This is a free service from FDA to provide occasional updates from OCP regarding newly approved therapies, new regulatory and scholarly publications, upcoming events and other items of interest. Subscribe today or click the button below and select Clinical Pharmacology Corner under Drugs.
We always welcome your thoughts regarding the format, content, and utility of this communication. Comments may be sent via email to ocp@fda.hhs.gov.
This communication was prepared by Office of Clinical Pharmacology, Office of Translational Sciences, CDER, FDA.
|
|
|
|
